Selective laser trabeculoplasty as a first-line therapy: a review

Area of Science:

• Ophthalmology
• Glaucoma Management
• Medical Technology

Background:

• Poor adherence to glaucoma medications is a significant clinical challenge.
• Nonadherence leads to treatment failures and disease progression.
• There is a need for treatments that reduce patient burden.

Purpose of the Study:

• To review the evidence supporting Selective Laser Trabeculoplasty (SLT) as a first-line therapy for glaucoma.
• To highlight SLT's potential to overcome medication adherence issues.
• To assess SLT's efficacy and cost-effectiveness compared to traditional treatments.

Main Methods:

• Review of existing clinical studies and evidence on SLT efficacy.
• Analysis of SLT's impact on intraocular pressure (IOP) in open-angle glaucoma.
• Comparison of SLT with topical glaucoma medications regarding patient adherence and cost.

Main Results:

• Selective Laser Trabeculoplasty (SLT) effectively lowers intraocular pressure (IOP) in most open-angle glaucoma patients.
• SLT is a cost-effective alternative to daily eye drops.
• SLT eliminates the problem of patient nonadherence to medication regimens.

Conclusions:

• SLT is a viable and evidence-supported first-line treatment option for open-angle glaucoma.
• Its ability to reduce IOP and bypass adherence issues makes it a valuable therapeutic choice.
• Further research supports SLT's role in improving glaucoma management outcomes.